GlassScriptPhysician profile
Vikram Prakash
NPI 1972815983
$15,064.53
in general payments reported to CMS, 2019-2025
16 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.31 · 2022: $179 · 2023: $547 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,976 · Consulting Fee: $5,400 · Food and Beverage: $865 · Education: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,975.62 |
| Consulting Fee | $5,400.00 |
| Food and Beverage | $864.62 |
| Education | $613.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $14,070.20 | 2025 | Ctexli, Cholbam |
| Acadia Pharmaceuticals INC | $215.29 | 2023-2025 | Daybue |
| Ucb, INC. | $173.40 | 2023-2025 | Fintepla, Briviact |
| Jazz Pharmaceuticals INC. | $159.18 | 2022-2025 | Epidiolex |
| Cadwell Industries, INC | $156.00 | 2023 | |
| Neurelis, INC. | $112.10 | 2022-2025 | Valtoco |
| Biogen, INC. | $31.31 | 2020 | |
| Abbvie INC. | $30.73 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $23.69 | 2023 | Fycompa |
| Nobelpharma America, LLC | $23.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.50 | 2023 | Koselugo |
| Travere Therapeutics, INC. | $16.01 | 2023 | Cholbam |
| Eisai INC. | $15.97 | 2023 | |
| Aucta Pharmaceuticals, INC. | $14.77 | 2025 | Motpoly Xr |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Prakash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.